IMPORTANCE Substantial shifts in perception and policy regarding cannabis have recently occurred, with use of cannabis increasing while its perceived harm decreases. One possible risk of increased cannabis use is poorer cognitive functioning, especially in youth.
S ubstantial shifts in the legality and public perceptions of cannabis have recently occurred in the United States. Cannabis use has increased, while the perception of its harms has decreased. 1, 2 In view of these trends, it is of considerable public health importance to delineate potential risks of cannabis use. However, scientific debates about physical and mental health consequences of cannabis remain unresolved. A critical question concerns potential cognitive dysfunction associated with cannabis use during adolescence and early adulthood, when use typically begins and substantial neurodevelopment continues to occur. To address this question, we conducted a meta-analysis specifically examining studies of cognitive functioning in adolescent and young adult cannabis users.
Adolescence is a period of dynamic neurobiological and behavioral changes. Substantial increases in cognitive capacities, particularly in executive functioning, 3 occur alongside marked neurodevelopmental changes (eg, maturation of prefrontal networks) that continue into the mid-20s. 4, 5 Because of this prolonged neurodevelopmental period and the potential involvement of the endocannabinoid system in such changes, 6, 7 concerns have increased regarding use of cannabis during this putative critical period of brain development. 8, 9 While there is consensus that acute cannabis intoxication results in cognitive deficits, residual cognitive effects from cannabis (ie, ones that persist after acute intoxication) are still debated, particularly after a period of abstinence. Numerous studies in adolescents and young adults have reported associations between frequent or early-onset cannabis use and poorer cognitive performance in tasks requiring executive functioning, attention, and episodic memory. [10] [11] [12] [13] [14] However, findings are somewhat inconsistent, 15, 16 with several explanatory and confounding variables contributing to variability; these include psychiatric and substance use comorbidities, frequency of cannabis use, and length of abstinence. [17] [18] [19] [20] Qualitative reviews of this literature have provided valuable insights, and most have concluded that adolescents and young adults are at heightened risk of cannabis-associated cognitive deficits, especially with early cannabis use. 8, 15, 21, 22 However, qualitative reviews can be selective; they rely primarily on statistical significance, typically do not conduct analyses of potential bias, and cannot provide accurate estimates of the magnitude of associations or influence of important variables that might contribute to variability in findings. Metaanalysis is a powerful method for synthesizing results across existing literature and examining whether explanatory variables affect variability in outcomes. Meta-analysis also addresses inconsistences by standardizing outcomes and diminishing the effects of varying statistical power. To date, 3 meta-analyses of adult cannabis users exist, [23] [24] [25] reporting small negative associations between attention, learning, memory, and executive functioning and frequent or heavy cannabis use. Yet effects were almost undetectable in studies that require users to maintain a few days to weeks of abstinence prior to assessment. 23, 24 However, a meta-analysis has not been conducted specifically in adolescents or young adults. In this study, we extend prior qualitative reviews by providing quantitative estimates of potential associations between heavy/ frequent cannabis use and cognitive functioning in adolescents and young adults. We also examined potential associations between variability in effect sizes and a predetermined set of explanatory variables, including study design and subject characteristics proposed to influence cognition in cannabisusing youth.
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Methods
Study Eligibility
We followed Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. 26 We began by defining a priori meta-analysis study inclusion criteria as any study that (1) assessed human adolescents and/or young adults (with a mean age of 26 years or younger, to include potentially sensitive neurodevelopmental periods 22 ); (2) identified heavy, frequent, and/or problematic cannabis use as the primary variable of interest; (3) did not solely identify cannabis as a comorbidity to another substance use or mental health disorder; (4) did not focus on acute effects; (5) included an appropriate comparison group; (6) reported at least 1 standardized neurocognitive test; (7) was written in English; and (8) provided sufficient data to calculate effect sizes. These criteria were intentionally designed to provide a comprehensive representation of existing research while also allowing the empirical examination of relationships between variability in study methods or study samples and effect sizes. (Details are presented in the eMethods in the Supplement.) Only observational, cross-sectional studies were included. Reliable estimates for longitudinal studies were indeterminable; there were few such studies, with heterogeneity in length of follow-up and methods of reporting cognitive data, and we believed that inference would be imprecise and unreliable with this small number of heterogeneous studies. However, baseline data from longitudinal studies were used where available.
Data Extraction
Study information was independently extracted by 2 researchers (S.T.S. and J.D.J.), with discrepancies in coding resolved with by a third researcher (J.C.S.). Because certain cognitive domains may have different sensitivities to cannabisassociated effects, 15 raters classified tests into domains based on evidence of construct validity. These domains were attention, learning, delayed memory, speed of information processing, verbal/language, visuospatial, motor functioning, and executive functioning (eMethods in the Supplement).To examine specific subcomponents of executive functioning, this domain was separated into abstraction/shifting, updating/ working memory, and inhibition subdomains based on a well-supported model of executive functioning. 27, 28 See eTable 1intheSupplement for tests in each cognitive domain.
Effect Size Calculation
We used the standardized mean difference statistic (d)asthe measure of effect size, applied Hedges and Olkin correction for small sample bias, 29 and used the variance for each d to determine a weighting factor for the unbiased effect size. Measures where low scores indicated better performance were adjusted so that a negative d indicated worse performance in the cannabis group. Funnel plot tests and exploratory analyses were conducted to examine potential small study bias including the method of Egger et al 30 to test for small study effects. Since no trim-and-fill method exists for multivariate mixed-effects meta-analysis, the Duval and Tweedie trim-and-fill method 31 for random-effects analyses provided an estimate of potentially missing effect sizes.
Statistical Analyses
Analyses were conducted using a mixed-effects multivariate model (eMethods in the Supplement). 32, 33 Since most studies reported multiple cognitive measures, this method was chosen to allow for multiple outcomes per study. A multivariate model allows for multiple correlated within-study effect sizes, takes the hierarchical (clustered) data structure into account, and permits different cluster sizes (ie, effect sizes per study).
A framework for such analyses is provided by Generalized Linear Latent and Mixed Models (GLLAMM) implemented in Stata version 13 (StataCorp), 34 which we have applied in prior meta-analyses. 35, 36 We defined a 2-level mixed-effects model; level 1 is represented by effect sizes within studies, and level 2 is represented by different studies. This model examines variability of effect sizes between studies (random factor) and associations between various explanatory variables (fixed factors) and effect sizes. Fixed-effects and random-effects parameters and their variances and covariance are estimated via adaptive quadrature, a robust and flexible numeric integration approach allowing heteroscedastic level 1 variances.
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Results
Preliminary Analyses
There were 69 eligible studies (Figure 1 ; Table) with 8727 participants, including 2152 cannabis users and 6575 comparison participants who had minimal cannabis use. Studies were published between 1973 and 2017. We coded 384 effect sizes from 69 studies (mean (SD), 9.46 [5.32] ; range, 1-17). Cannabis users in the studies had a mean (SD) age of 20.6 (2.8) years and were 68.1% male. Comparison participants had a mean (SD) age of 20. 8 (3.4) years and were 55.8% male. Studies included were predominantly conducted in the United States, United Kingdom, Europe, and Australia. Cannabis users had a mean (SD) age at cannabis use initiation of 15.2 (1.5) years. The mean (SD) time of abstinence required by the studies was 152. 7 (335.2) hours. Twenty-two studies (32%) reported either 0 hours of abstinence or no specificity in abstinence criteria, 32 studies (46%) reported between 1 and 72 hours of abstinence, and 15 studies (22%) reported greater than 72 hours of abstinence. We first tested a model without explanatory variables, 35, 36 revealing that the overall mean neurocognitive effect size was d was −0.247 (SE, 0.038; 95% CI, −0.32 to −0.17), and the between-study variance estimate was 0.070 (SE, 0.018; P < .001), indicating that variance between studies was significantly more than that explained by sampling error alone. eFigure 1A in the Supplement displays a funnel plot of effect size estimates against their standard error. Visual inspection of this funnel plot revealed asymmetry, and the test of Egger et al 30 for small study effects revealed significant bias (t = 4.70; P < .001). The Duval and Tweedie trim-and-fill method filled an additional 44 effect sizes and reduced the effect size by approximately 37.9% in random-effects analyses (from d = −.206; 95% CI, −0.24 to −0.16 to d = −0.128; 95% CI, −0.17 to −0.09; P < .001), although a significant effect size remained (eResults in the Supplement). However, the exact reduction in magnitude should be interpreted with caution. P < .001). However, there were no significant differences in effect size estimates between learning, delayed memory, attention, speed of information processing, or executive functioning domains after applying Bonferroni corrections.
Neurocognitive Domains
Follow-up Analyses
Follow-up analyses were performed with several predetermined explanatory variables, including age at first cannabis use, sample sociodemographic characteristics, clinical characteristics (eg, depression), publication year, mean hours of abstinence, and length of required abstinence (longer than 72 hours vs 72 hours or less), given prior literature hypothesizing such moderating effects (hereafter, k indicates the number of studies corresponding to each variable). 15, 21, 22 Subgroup analyses revealed no significant differences in effect sizes by the age category (adolescents or adults) of the sample population (eFigure 2 in the Supplement), early vs late cannabis use onset (ranging from 15 to 18 years old as defined by each individual study; studies were inconsistent in what age was considered early onset), whether studies matched groups by alcohol use, or period of publication (eFigure 3 in the Supplement). Further, mean age, mean age at first use, and betweengroups difference in depression were not associated with variability in effect size estimates (eResults in the Supplement). However, studies with treatment-seeking samples (k = 12; n = 581; d, −0.43; 95% CI, −0.62 to −0.24) showed larger magnitude effect sizes (χ 2 1 = 4.32; uncorrected P = .04) compared with non-treatment-seeking samples (k = 56; n = 8146; d, −0.22; 95% CI, −0.29 to −0.14) in a test for subgroup differences.
At an uncorrected threshold for multiple comparisons, mean hours of reported abstinence (which were available for k = 28; n = 1661; β = 0.059; P = .04) in each study was associated with variability in effect sizes, such that longer abstinence periods were associated with reductions in effect size magnitude. Furthermore, as shown in Figure 3 , studies requiring an abstinence period longer than 72 hours (k = 15; n = 928) had an overall effect size that was not significantly different from0(d = −0.08, 95% CI, −0.22 to 0.07; P = .29) and was significantly smaller than studies with less stringent abstinence criteria (k = 54; n = 7799; χ 2 1 = 6.36; P = .01).
Discussion
Prior reviews have concluded that frequent use of cannabis impairs cognitive functioning in several domains, with greater deficits associated with adolescent vs adult onset of use. 8, 21, 22, 25 Our quantitative synthesis of data from 69 studies of adolescents and young adults revealed statistically significant but small cognitive effects associated with heavy/frequent cannabis use. These effects did not vary systematically by the age range studied or the age at which cannabis was initiated, although help-seeking samples in treatment evidenced slightly larger effects. Importantly, increasing abstinence was associated with smaller effect sizes, and studies that required an abstinence period from cannabis of longer than 72 hours had a very small, nonsignificant effect size. The magnitude of these deficits and their reduction by abstinence are consistent with prior meta-analyses conducted in adults with more chronic use patterns. 23, 24 Taken together, our analyses suggest a detectable but limited association between cannabis use and cognitive functioning in adolescents and young adults; for a majority of individuals, such effects may be of questionable clinical significance, especially after sustained abstinence. These findings converge with a recent report from the National Academies of Sciences, Engineering, and Medicine, 91 which highlighted the multitude of confounders present in many studies and concluded that there is significant uncertainty about the presence of cannabis-associated cognitive deficits after sustained abstinence.
Findings Across Cognitive Domains
We found variability in effect sizes across cognitive domains, with the largest effects in learning and delayed memory, executive functioning, speed of processing, and attention. However, effect sizes in these domains were similar and within a relatively constricted range (mean d, −0.33 to −0.21). It is important to consider the practical implications of these effect size magnitudes. Although traditional conceptualizations of effect size magnitude do not necessarily correspond to clinical signifi- cance, all effect sizes in this study were below one-third of a standard deviation. Thus our results do not support the conclusion that frequent cannabis use is associated with large or even medium magnitude deficits in memory, attention, or other aspects of cognitive functioning. Although it could be argued that neurocognitive testing lacks sensitivity to detect cognitive abnormalities in cannabis abusers, prior meta-analyses in substances such as alcohol, 92 methamphetamine, 35 benzodiazepines, 93, 94 and cocaine 95 have shown medium to large effect sizes, arguing against a lack of sensitivity. Moreover, recent large-scale structural neuroimaging studies also report conflicting data on cannabis-associated alterations in adolescents and adults.
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Length of Abstinence and Reduction of Effect Sizes
A notable finding in this meta-analysis was that the length of abstinence was associated with variance in effect sizes across studies, albeit at thresholds uncorrected for multiple comparisons. Although accurate measurement of abstinence is challenging because only 14 studies reported monitored abstinence, a longer required length of abstinence was associated with smaller magnitude effect sizes. Similarly, increasing the reported (as opposed to required) length of abstinence was associated with decreased magnitude of effect sizes. Moreover, studies with abstinence periods longer than 72 hours had small, nonsignificant effect sizes that were significantly less than studies with shorter abstinence periods, suggesting that some effects observed in studies associating cannabis use with cognitive dysfunction may be due to residual effects of recent use or withdrawal, rather than persistent changes associated with chronic use. 23,101 Thus, small negative associations between continued cannabis use and cognitive functioning may diminish after sustained abstinence. However, these findings contrast with those from a large longitudinal study 102 and a recent systematic review in adolescents and adults. 25 Discrepancies with the latter may reflect differences in the age range covered, study selection, and methods of analysis.
Association of Age With Effect Sizes
Age did not influence cognitive effect size estimates. In fact, older samples had slightly larger (nonsignificant) effect sizes overall. Additionally, studies of early-onset cannabis users did not have significantly larger effects than studies examining lateonset users. Perhaps studies not specifically focusing on earlyonset users nonetheless included substantial numbers of these individuals, because heavy cannabis users are more likely to initiate use at an early age. Taken together, these results do not support a heightened risk for poor cognitive outcomes in cannabis-using adolescents compared with adults, although such differences may emerge with adolescent onset and long-term frequent use, as previously reported. 102, 103 Only longitudinal data can delineate whether initiation of cannabis use during adolescence vs adulthood results in greater risks for brainbehavior functioning.
Considerations for Interpretation
The magnitude of these effect sizes and potential implications of findings should be considered in the context of additional relevant factors. First, it is critical to highlight that all psychoactive substances are associated with risks of use, and cannabis is no exception. Importantly, the data reported here do not address associations between cannabis use and other significant physical and mental health outcomes, such as negative lung functioning outcomes, deleterious outcomes on motivation, or risk for psychosis, which have been reported as heightened with chronic or early use.
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A second consideration is that functional outcomes may ultimately be more important than measures of cognitive functioning, and some studies suggest particular risks of early, heavy use for academic and occupational outcomes. 107, 108 However, findings regarding academic functioning have been inconsistent and may depend on other substance use or familial factors. 109, 110 These associations are obviously complex and will require more specific prospective modeling. Third, there is likely heterogeneity in who is at greatest risk of brain-behavior problems associated with frequent cannabis use. Studies show interparticipant variability in behavioral and brain response to cannabis, 111,112 which could contribute to individual differences in cognitive outcomes. Moreover, for certain individuals, small effects could be clinically meaningful because of individual differences influencing cognitive functioning (eg, socioeconomic status). On the other hand, most of the studies that were included predominantly enrolled frequent cannabis users or those with cannabis use disorders, and findings may not generalize to more occasional users or to those administered cannabinoids in medical settings. Fourth, reported effect sizes may actually be overestimates, considering results from measures of bias. Smaller published studies often show larger effects than large studies, which can bias meta-analyses. 30 Several factors can lead to these effects, 113 including methodological differences or publication bias, in which statistically significant findings are more likely to be published. 114 We found potential small study effects in this literature, and a data augmentation method that imputes missing studies (accounting for potential bias) suggested that effect sizes might be inflated. Furthermore, though some studies used normative neurocognitive data that adjust for influential demographic factors, our analyses primarily used raw scores to calculate effect sizes. As such, results do not account for sociodemographic, psychiatric, or substance use confounders, which are common in case-control studies of cannabis 115, 116 ; effects may be further attenuated once such factors are accounted for. Finally, we cannot make conclusions about the causal contribution of cannabis to alterations in cognitive functioning since results do not account for cognitive deficits that may have existed prior to cannabis use initiation. Adolescents at risk of substance use problems may display cognitive vulnerabilities, 17,117-120 which could partially contribute to cognitive findings described here, although they do not exclude the possibility of additional deficits. Furthermore, our data do not address associations between cannabis use and cognitive functioning over longer periods, although some included studies did examine chronic cannabis users and outcomes after protracted abstinence. Consideration of results from longitudinal studies offers conflicting evidence Neuropsychological meta-analyses are hindered by variability in tests administered across a body of literature, creating challenges in assigning outcomes into specific cognitive domains. Although tests purport to measure specific cognitive functions, most tests involve multiple cognitive processes. Thus, cautious interpretation of effect size differences between domains is warranted. However, this limitation is diminished in our meta-analysis given the substantial overlap in effect size magnitudes. Furthermore, studies often report multiple neurocognitive outcomes and focus primarily on significant between-group differences as evidence of cognitive deficits. We attempted to mitigate this outcome selection bias by selecting measures based on construct validity and not statistical significance, and avoided selecting multiple indices from individual tests that measure similar constructs. Moreover, we used sophisticated analytic models to account for within-study correlations. Together, these methods reduce the problems of multiple comparisons evident in this literature.
Conclusions
In light of the changing perceptions of cannabis use and an evolving policy landscape surrounding cannabis, understanding the potential risks of cannabis use for mental health and brain functioning is of paramount importance. In the first quantitative synthesis of 69 studies examining frequent or heavy use of cannabis by adolescents and young adults, we found statistically significant but small negative effect sizes in cognitive functioning associated with cannabis. Inconsistent with conclusions from previous reviews, we found little evidence for more severe effects with cannabis use at earlier ages or specifically in adolescence. Moreover, the data suggest associations between length of abstinence and restored cognitive functioning, with greater abstinence associated with smaller group differences. Furthermore, we found very small, nonsignificant effect sizes in studies that required more than 72 hours of cannabis abstinence. Large-scale longitudinal studies are needed to examine the effects of sustained, heavy cannabis use and identify genetic factors, individual differences, and cannabis use parameters that may affect risk for brainbehavior dysfunction in individuals who use cannabis. This supplementary material has been provided by the authors to give readers additional information about their work.
Supplementary Methods Search Strategies and Selection of Studies
Literature searches using the keywords cannabis or marijuana paired with adolescent or young adult and cogniti*, neuropsycholog*, or domain-specific keywords (e.g., memory) were independently conducted by two reviewers using four electronic databases: PubMed, PsycINFO, Academic Search Premier, and Scopus. As an example, the following electronic search was conducted in PubMed: (((cannabis[Title/Abstract] OR marijuana[Title/Abstract]) AND (adolescent OR "young adult") AND (cognition OR cognitive OR neuropsycholog* OR memory OR attention OR concentration OR working memory OR executive function* OR inhibition OR planning OR shifting OR switching OR verbal fluency OR language OR speed of information processing OR processing speed OR psychomotor OR visuospatial)) NOT Review[ptyp] AND Humans[Mesh] AND English [lang] ). The reference lists of relevant reviews were also hand searched to identify omissions in our literature search.
See Methods in main text for meta-analysis inclusion criteria. Because we were interested in heavy/frequent cannabis use during potentially sensitive neurodevelopmental periods, we included studies in which the cannabis group had a mean age of 26 or less (it should be noted that 30 studies had an upper age range that may have been older than 26, though age range was not commonly reported in young adult studies). Although there is variability in trajectories of brain gray and white matter development and debate about when significant neurodevelopment decelerates, age 25 or 26 is when the deceleration in most changes in structural brain measures appears to occur.
1 Because this estimate of neurodevelopmental age may be imprecise, we also examined the mean age, age range of the cannabis sample, early versus late onset of cannabis use, and age at first cannabis use as explanatory variables to examine whether age influenced the magnitude of effect sizes.
For studies that examined cognitive functioning in cannabis users with severe psychiatric disorders (e.g., schizophrenia), we only included groups without such disorders. Similarly, studies that identified cannabis use as a significant comorbidity to another drug of interest (e.g., methylenedioxymethamphetamine [MDMA]) were excluded. Studies that reported cognitive data only from tests administered during functional neuroimaging were excluded due to the varying characteristics of the tests and their typically unexplored validity as behavioral markers of cognitive dysfunction. When studies included more than one affected group (e.g., early and late users) with independent data available, we used data from both groups but halved the comparison group sample size to avoid oversampling, as previously recommended. 2 For studies reporting cognitive functioning data in both early and later abstinence periods from the same users, 3, 4 we included data from later abstinence periods in order to have sufficient data to address questions regarding abstinence. When sufficient data to calculate effect sizes were unavailable, study authors were contacted in an attempt to obtain data. Studies with shared authors were carefully reviewed to minimize inclusion of overlapping data.
Studies varied in their inclusion criteria for cannabis user groups (see eTable 1). Some studies provided limited information regarding criteria for cannabis group inclusion, although their cannabis group reported frequency and/or quantity of use that was similar to those of other studies with more specific criteria, and such studies were therefore included. However, this variability created challenges in creating standards for meta-analytic study inclusion. We decided to be inclusive to provide a comprehensive overview of the literature examining frequent/heavy cannabis use and cognitive functioning in adolescents and young adults. In addition, studies were inconsistent in their classifications of early cannabis use, with classification of early age of initiation ranging from 15 to 18. Therefore, we used the authors' classification of early use in each individual study to define early cannabis use for analytic purposes (see below).
Meta-analysis data presented in this study and a corresponding data dictionary are available on the Open Science Foundation website (http://osf.io/z2qwf).
Effect Size Calculation
We used the standardized mean difference statistic (d) as the measure of effect size, which was calculated as d = (M e -M c )/S p , where M e and M c are the mean scores on a neuropsychological test for the cannabis and comparison groups, respectively, and S p is the pooled within-group standard deviation. For studies in which mean scores and standard deviations were not reported, standardized mean difference effect sizes were derived from tvalues based on independent t-tests or F-ratios from a two-group one-way analysis of variance. 5 If standard error of the mean was reported instead of standard deviation, transformation to standard deviation was conducted by multiplying the standard error by the square root of the sample size. When values were only displayed in figures and the authors could not provide data, 3 numerical values were extracted from figures using WebPlotDigitizer version 3.12 (http://arohatgi.info/WebPlotDigitizer/app/). By convention, d values of .2, .5, and .8 correspond to small, medium, and large effect sizes, respectively, 6 although it should be noted that these categorizations are broad and do not necessarily signify levels of practical significance.
Raters independently classified tests into domains based on evidence of construct validity. These domains were attention (e.g., Continuous Performance Test), learning (e.g., California Verbal Learning Test-Second Edition [CVLT-2] Trials 1-5), delayed memory (e.g., CVLT-2 Delayed Recall), speed of information processing (e.g., Wechsler Adult Intelligence Scale, Third Edition [WAIS-III] Digit Symbol), verbal/language (e.g., Verbal Fluency), visuospatial (e.g., Rey Complex Figure Copy) , motor functioning (e.g., Grooved Pegboard), and three subdomains of executive functioning, including abstraction/shifting (e.g., Wisconsin Card Sorting Test), updating/working memory (e.g., n-back), and inhibition (e.g., Stop Signal Paradigm). Note that "learning" as identified here is synonymous with "immediate memory," while "delayed memory" is synonymous with "delayed recall." If a study included multiple outcomes from a single neurocognitive test that assessed the same construct (e.g., CVLT-2 Delayed Free Recall and Delayed Cued Recall), consensus was used to select the outcome with the greatest evidence of construct validity (e.g., Delayed Free Recall) to reduce the problem of multiple comparisons. We chose not to examine IQ specifically as an outcome since many studies used a measurement of IQ or IQ estimate to match groups, which would bias effect sizes.
The following information was extracted from each study: (a) participant demographic variables (e.g., mean age), (b) cannabis use characteristics (e.g., mean age of cannabis use onset, frequency of cannabis use), (c) other clinical characteristics (e.g., comorbid alcohol use, length of cannabis abstinence), (d) study inclusion/exclusion criteria, (e) sample size, and (f) summary statistics for the calculation of effect sizes.
Additional Explanatory Variables
We examined a number of predetermined additional study-level variables as explanatory variables based on prior research, including mean hours of reported abstinence, study abstinence criteria, the between-groups standardized mean difference of a study's reported depression measure, time period of publication, whether groups in a study were matched on alcohol use, and whether the sample was a community-based or clinical sample. Given the multiple variables examined, we defined a Bonferroni correction level of p = 0.008 and also reported results unadjusted for multiple comparisons.
We examined the age of a sample as a categorical variable, representing adolescent (age 10 to 18; k = 15, N = 790), young adult (age 19 to 26; k = 41, N = 3457), or mixed adolescent and young adult (k = 13, N = 4480) sample. Similarly, we examined age at first use (available for k = 45 studies) as a categorical variable for subgroup analyses, representing early use of cannabis (k = 13, N = 817) and late use or nonspecific onset of cannabis use (k = 56, N = 7910).
Mean hours of reported abstinence was positively skewed and log transformed for further analysis. To examine clinically relevant cannabis abstinence criteria, we also divided study abstinence criteria into a three-level variable representing: (1) none or no specificity in abstinence criteria (k = 22, N = 5768); (2) equal to or less than 72 hours of abstinence (k = 32, N = 2031); and (3) greater than 72 hours of abstinence (k = 15, N = 928). Seventy-two hours was chosen as a cutoff to correspond to the post-peak period for most cannabis withdrawal symptoms. 7 Subgroup analyses combined groups 1 and 2 above to compare to group 3. However, we present data in Figure 3 in the main text to show that the subgroup with unknown or zero abstinence levels were not the primary contributor to these differences.
Given increasing levels of THC in cannabis, some have proposed the potential for increased cannabisassociated deficits in recent years due to this increased potency. We present estimated effect sizes for each year of publication across studies in eFigure 3 so that readers can visually examine whether cannabis is associated with any trends in effect size magnitude by year. Further, we also created a three-level variable, representing studies published before the year 2000 (k = 6, N = 376), from 2000-2009 (k = 17, N = 882), and after 2010 (k = 46, N = 7469) to test in subgroup analyses whether associations between frequent cannabis use and cognitive functioning were different in older vs. more recent studies.
A depression measure for both groups, necessary to construct between-groups standardized mean differences, was available for k = 24 studies (N = 1408). Only k = 23 studies (N = 1708) matched groups by alcohol use characteristics.
We also conducted secondary analyses to examine the consistency of results and protect against concerns regarding variable selection. To this end, we examined whether analyses of continuous variables representing early use of cannabis (i.e., mean age at first cannabis use, available for k = 45, N = 6454) sample age (i.e., mean age of each cannabis sample, available for k = 68, N = 8675), and abstinence criteria (e.g., required hours of abstinence, available for k = 69, N = 8727) were consistent with analyses of the categorical variables described above. Required hours of abstinence was coded as zero if no information on abstinence was reported. This variable was positively skewed and log transformed for further analysis.
It was not possible to code a number of factors that could affect the interpretation of results. No studies reported the use of neuropsychological performance validity tests to examine the influence of effort on neuropsychological test performance, despite the relevance of such measures for predicting cognitive performance in individuals with psychiatric disorders. 8 There were also limited means for classifying cannabis use severity, as there was heterogeneity in the measurement and reporting of cannabis use parameters.
Analyses
Analysis of Bias
It is well known that studies with small sample sizes that are published in the research literature are likely to show larger effects than studies with larger samples, which can lead to small study effects in meta-analyses. 9 To examine potential small study bias in the literature, funnel plot tests and exploratory analyses were conducted. These procedures included visual inspection of the funnel plot, the method of Egger and colleagues 9 to test for small study effects, and the trim-and-fill method of Duval and Tweedie 10 to fill potentially missing effect sizes. We interpreted significant funnel plot asymmetry as potentially indicative of publication bias across the literature. This asymmetry often occurs when smaller studies with low precision and null or unexpected effects are systematically missing from the published literature. The trim-and-fill method is a sensitivity analysis to follow up on potentially asymmetrical funnel plots. The method estimates the number of potentially missing effect sizes from a meta-analysis and examines the effects of imputing the missing effect sizes. Since, to our knowledge, there is no trim-and-fill method for mixed effects meta-analysis, we ran a random effects meta-analysis on all data and adjusted using the standard trim-and-fill method. Given that this analysis was not identical to our primary mixed effects analyses, the exact reduction in effect size magnitude and the number of filled effect sizes generated from this analysis should be interpreted with caution.
Statistical Analyses
Our analyses used a multivariate mixed-effects model for several theoretical and practical reasons. First, this method was chosen to allow for multiple outcomes per study. Most studies of neurocognitive functioning report multiple cognitive outcomes since multiple tests are typically required to have reliable data that assesses cognitive functioning across several ability areas. Although some meta-analyses conduct multiple, separate univariate metaanalyses when encountering multiple outcomes per study, this approach unfortunately does not allow the comparison and synthesis of effect sizes within studies and can lead to partially redundant analyses. Some metaanalyses simply allow a single study to contribute more than one effect size estimate when multiple outcome measures are reported. However, effect sizes within such studies are likely non-independent. Riley 11 has demonstrated that treating multiple effect sizes within studies as though they were statistically independent may lead to biased estimates and invalid conclusions, unless the within-study variance is small relative to the between-study variance and the within-study covariances differ little across studies. Although some meta-analyses simply average data across domains or select a single measure to represent a functional domain, this process ignores the richness of data and could introduce significant biases.
The statistically and substantively more sound approach is a multivariate model that allows for multiple correlated within-study effect sizes, takes the hierarchical (clustered) data structure into account, and permits different cluster sizes (i.e., different number of effect sizes per study). A multivariate mixed-effects model for metaanalysis also allows us to increase generalizability instead of allowing inferences only about this particular set of studies. To apply this model to meta-analytic data, we first calculated d and determined the sampling variance of each effect size, and we defined a two-level mixed effects model, where level 1 is represented by multiple effect sizes within studies, and level 2 is represented by the different studies. The model considers the level-1 effect size variances as fixed/known (as calculated).
eResults. Results. Preliminary Analyses
eFigure 1A displays a funnel plot of effect size estimates against their standard error across the 69 studies, revealing asymmetry. We applied the trim and fill method of Duval and Tweedie 10 to examine the effect of filling the funnel plot with potentially missing effect sizes. As shown in eFigure 1B, this method filled an additional 44 studies, with the effect size (reported as mean [95% CI]) being reduced from d = -.206 [-0.24, -0.16 ] to d = -.128 [-0.17, -.09] , although this adjusted mean effect size was still significant (p < .001).
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Follow-up Analyses
As shown in eFigure 2, subgroup analyses showed no differences in effect size magnitude between studies that only included adolescents (18 years old and under; d=-.19) , only included young adults (d=-.26), or included mixed adolescent/adult samples (d=-.26) ( 2 (2)=0.37, p=.83). Secondary analyses showed no significant differences in effect size magnitudes by mean age ( =-.01; p=.29) .
In subgroup analyses, no significant differences in effect size magnitudes were found between studies examining early use (d=-.28) versus late use or nonspecific samples (d=-.24; 2 (1)=0.15, p=0.70). Secondary analyses of age at first use showed that this variable was also not associated with variability in effect sizes (ß=.003, p=.92).
There was no effect of between-groups discrepancy (i.e., standardized mean difference) in depression scores ( =.14; p=.54) on the magnitude of effect sizes. There was also no effect of whether groups were matched on alcohol use in a study ( 
